Making sense of machine learning. Key slides on Discriminative AI vs Generative AI. Liubov Arbeeva @RheumNow #ACR25 https://t.co/Xli1mSTVQf

• https://x.com/synovialjoints/status/1983245331266420787/photo/1

Dr. John Stone on IgG4RD ⬆️ common in males ⬆️internal organ involvement 🔸Mimics cancer 🔸Indolence makes it dangerous —-> organ complications Diagnosis highly dependent on the rheumatologist based on clinical features, serologies, imaging & pathological data #ACR25 @Rheumnow https://t.co/St4EbA7Dcj

• https://x.com/RHEUMarampa/status/1983242946821390698/photo/1

US Electronic Health Record cohort 2000+pts Incidence Heart Failure over 10 yrs 6.8% HF asso w/ Older Male Lower eGFR Hypertensive medication Diabetes TTMTS MTX, TNFi Higher CRP Probably surrogates for High Disease Activity... How do we detect it? Maybe not by using the https://t.co/s9SjEyk3WF

• https://x.com/AurelieRheumo/status/1983242428447424710/photo/1
• https://x.com/AurelieRheumo/status/1983242428447424710/photo/1

@RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too. #ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4

• https://x.com/drdavidliew/status/1983238835724247300/photo/1

@RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile #ACR25 FDA Update @RheumNow https://t.co/h6bf4roGzB

• https://x.com/drdavidliew/status/1983238079105409478/photo/1
• https://x.com/drdavidliew/status/1983238079105409478/photo/1
• https://x.com/drdavidliew/status/1983238079105409478/photo/1

Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card. We’re not exactly overwhelmed with proven options for FM, the unmet need is so great, so the more, the better. #ACR25 FDA session @RheumNow https://t.co/wwWijl3IyW

• https://x.com/drdavidliew/status/1983236387387388230/photo/1

Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI seems to be the big concern, with Reporting Odds Ratio of >17. @RheumNow #ACR25 Abstr#2519 https://t.co/1LoDvRHkqa

• https://x.com/RichardPAConway/status/1983234558985417164/photo/1

@US_FDA rheumatology approvals, 2025 #ACR25 @RheumNow https://t.co/uVLWqBx45m

• https://x.com/drdavidliew/status/1983234312305824068/photo/1

IgG4 - Rare but Rx Several studies #ACR25 @ACRheum were presented Outcome measures Rx #steroids #CD19 mAb #Inebilizumab 👍+RCT reduction of flares BTKi #Rilzabrutinib #Zanubrutinib #JAKi +RCT of #tofacitinib +steroids vs pred @ACRheum @RheumNow #ACR25 1163 LB02 0239 1172 https://t.co/xC3wgaN9bk

• https://x.com/Janetbirdope/status/1983233945102659935/photo/1

Sjögren’s, decoded by Ab -->ESSDAI domains: • anti-SSA → glandular • anti-Ro52 / SCL70 → biologic activity • anti-nucleosome → pulmonary • anti-histone → pulmonary + cutaneous Distinct serologic–ESSDAI patterns may guide monitoring and management @RheumNow #ACR25 A#2295

#ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY showed Obinutuzumab induced near-complete depletion & significantly reduced plasma in kidney tissue vs PBO @RheumNow https://t.co/r1danWBM7D

• https://x.com/Yuz6Yusof/status/1983232738934030504/photo/1

In PsA, a predictive model using routine labs (NLR, LMR, ESR, C3, baseline DAPSA) identified TNFi responders with 100% sensitivity and 0.861 AUC. Supports biomarker-driven personalization of PsA treatment. Abstract#2371 @RheumNow #ACR25 https://t.co/lojQFfWsJi

• https://x.com/synovialjoints/status/1983232299035410566/photo/1

Agrawal et al. Case study of tofacitinib + bDMARDs in refractory IA. 7 SpA, 2 RA, 1 JIA. Effective and safe. @RheumNow #ACR25 Abstr#2338 https://t.co/Y0B3W4csJX

• https://x.com/RichardPAConway/status/1983230783952466190/photo/1

In RA, “strong bones” can give false reassurance. Pts with higher baseline BMD had faster bone loss, often tied to GC use and less osteoporosis treatment. Undermanagement, not biology, may drive decline. @RheumNow #ACR25 Abstract#2244 https://t.co/N421ESAUy9

• https://x.com/JihaRheum/status/1983230532231332183/photo/1